Evidence map›Paper›PMID 35045748›Full record

Trial reportThyroid : official journal of the American Thyroid Association2022

Enhancing Radioiodine Incorporation in

Vatche Tchekmedyian, Lara Dunn, Eric Sherman, Shrujal S Baxi, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra and 9 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thyroid : official journal of the American Thyroid Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Vatche TchekmedyianDepartment of Medicine, New York, New York, USA.
Lara DunnDepartment of Medicine, New York, New York, USA.
Eric ShermanDepartment of Medicine, New York, New York, USA.
Shrujal S BaxiDepartment of Medicine, New York, New York, USA.
Ravinder K GrewalDepartment of Radiology, New York, New York, USA.
Steven M LarsonDepartment of Radiology, New York, New York, USA.
Keith S PentlowDepartment of Medical Physics, New York, New York, USA.
Sofia HaqueDepartment of Radiology, New York, New York, USA.
R Michael TuttleDepartment of Medicine, New York, New York, USA.
Mona M SabraDepartment of Medicine, New York, New York, USA.
Stephanie FishDepartment of Medicine, New York, New York, USA.
Laura BoucaiDepartment of Medicine, New York, New York, USA.
Jamie WaltersDepartment of Medicine, New York, New York, USA.
Ronald A GhosseinDepartment of Pathology, New York, New York, USA.
Venkatraman E SeshanDepartment of Epidemiology and Biostatistics; New York, New York, USA.
Jeffrey A KnaufDepartment of Human Oncology and Pathogenesis Program; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
David G PfisterDepartment of Medicine, New York, New York, USA.
James A FaginDepartment of Medicine, New York, New York, USA.
Alan L HoDepartment of Medicine, New York, New York, USA.ORCID 0000-0002-6885-3742
Cornell University · USNew York Oncology Hematology · USMemorial Sloan Kettering Cancer Center · USCancer Research And Biostatistics · USColumbia University Irving Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE in Thyroid CancerP50CA172012 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A · 2014 to 2018
$10.3M
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancerR01CA201250 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HUMM, JOHN L, LARSON, STEVEN MARK · 2016 to 2020
$3.5M
Improving efficacy of radioiodine treatment of thyroid cancerR01CA249663 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A, HO, ALAN L. · 2021 to 2025
$2.3M
Targeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid CancerR01CA184724 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HO, ALAN L. · 2015 to 2017
$1.7M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA172012NCI NIH HHS R01 CA184724NCI NIH HHS R01 CA201250NCI NIH HHS R01 CA249663
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsThyroid NeoplasmsAntibodies, MonoclonalHumansIodine RadioisotopesMutationPositron Emission Tomography Computed TomographyProto-Oncogene Proteins B-rafVemurafenibAntibodies, MonoclonalAntineoplastic AgentsBRAF protein, humanIodine RadioisotopesProto-Oncogene Proteins B-rafVemurafenibBRAF mutantCDX-3379radioiodine refractory thyroid cancerredifferentiationvemurafenib

Identifiers

PMID35045748
PMCPMC9206492
OpenAlexW4206708280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.